HUDDINGE, Sweden I April 2, 2013 I ChronTech now has made the first analysis of 12 weeks treatment with interferon and ribavirin in patients with (n=17) or without (n=12) two monthly previous vaccinations with 500 µg ChronVac-C® administered with Inovio’s Medpulser. No serious adverse events were noted and the number of moderate adverse events were lower in the vaccinated group than in the non-vaccinated group. At treatment week 12, 71 % of the vaccinated group had less than 15 international units of HCV RNA as compared to 58 % in the non-vaccinated group. As regards to number of patients who were virus negative at treatment week 12 in the vaccinated group 65 % were HCV RNA negative as compared to 58 % in the non-vaccinated group. All in all the study shows that ChronVac-C® is very safe but the differences in treatment outcome so far were too low to be statistically significant.
“Obviously it is with mixed feelings we receive these results. We had hoped for a larger difference between the two groups. Possibly this could be explained by the fact that we in this study chose to giver fewer vaccination doses than in our previous study. However, we will have to await the ongoing analysis of the vaccine activated immune responses before we can draw any definite conclusions” says ChronTech’s CEO Anders Vahlne.
About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
SOURCE: ChronTech Pharma
Post Views: 202
HUDDINGE, Sweden I April 2, 2013 I ChronTech now has made the first analysis of 12 weeks treatment with interferon and ribavirin in patients with (n=17) or without (n=12) two monthly previous vaccinations with 500 µg ChronVac-C® administered with Inovio’s Medpulser. No serious adverse events were noted and the number of moderate adverse events were lower in the vaccinated group than in the non-vaccinated group. At treatment week 12, 71 % of the vaccinated group had less than 15 international units of HCV RNA as compared to 58 % in the non-vaccinated group. As regards to number of patients who were virus negative at treatment week 12 in the vaccinated group 65 % were HCV RNA negative as compared to 58 % in the non-vaccinated group. All in all the study shows that ChronVac-C® is very safe but the differences in treatment outcome so far were too low to be statistically significant.
“Obviously it is with mixed feelings we receive these results. We had hoped for a larger difference between the two groups. Possibly this could be explained by the fact that we in this study chose to giver fewer vaccination doses than in our previous study. However, we will have to await the ongoing analysis of the vaccine activated immune responses before we can draw any definite conclusions” says ChronTech’s CEO Anders Vahlne.
About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
SOURCE: ChronTech Pharma
Post Views: 202
